Combination Study Agreement Sample Contracts

AMENDMENT NO. 2 TO THE PHASE I/IB COMBINATION STUDY AGREEMENT

Combination Study Agreement • March 9th, 2020 • Corvus Pharmaceuticals, Inc. • Pharmaceutical preparations • California

• Contract Type
  Combination Study Agreement
• Filed
  March 9th, 2020
• Company
  Corvus Pharmaceuticals, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  California

THIS AMENDMENT NO. 2 TO THE PHASE I/IB COMBINATION STUDY AGREEMENT (this “Amendment”) dated as of August 1, 2019 amends the Phase I/IB Combination Study Agreement (the “Agreement”), made and entered into as of October 5, 2015, between Corvus Pharmaceuticals, Inc., having a principal office located at 863 Mitten Road, Suite 102, Burlingame, CA 94010 (“Corvus”), and Genentech, Inc., having a principal office located at 1 DNA Way, South San Francisco, CA 94080.

Combination Study Agreement

Combination Study Agreement • March 23rd, 2017 • BioLineRx Ltd. • Pharmaceutical preparations • New York

• Contract Type
  Combination Study Agreement
• Filed
  March 23rd, 2017
• Company
  BioLineRx Ltd.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

This Combination Study Agreement (“Agreement”) is made and entered into, effective as of September 6, 2016 (“Effective Date”), by and between Genentech, Inc., a Delaware corporation, having a principal place of business at 1 DNA Way, South San Francisco, California 94080 (“Genentech”) and BioLineRx Ltd., an Israeli company, having a principal place of business at Modi’in Technology Park, 2 HaMa’ayan Street, Modi’in 7177871, Israel (“BioLineRx”). Genentech and BioLineRx are each referred to herein individually as a “Party” and collectively as the “Parties.”

PHASE I/IB COMBINATION STUDY AGREEMENT BY AND BETWEEN GENENTECH, INC. AND CORVUS PHARMACEUTICALS, INC.

Combination Study Agreement • February 8th, 2016 • Corvus Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware

• Contract Type
  Combination Study Agreement
• Filed
  February 8th, 2016
• Company
  Corvus Pharmaceuticals, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Delaware

THIS PHASE I/IB COMBINATION STUDY AGREEMENT (“Agreement”) is made and entered into, effective as of October 5, 2015 (“Effective Date”), by and between Genentech, Inc., a Delaware corporation, having a principal place of business at 1 DNA Way, South San Francisco, California 94080 (“Genentech”) and Corvus Pharmaceuticals, Inc., a Delaware corporation, having a principal place of business at 863 Mitten Road, Suite 102, Burlingame, CA 94010 (“Corvus”). Genentech and Corvus are each referred to herein individually as a “Party” and collectively as the “Parties.”